Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) Versus Chemotherapy for Endometrial Carcinoma (ENGOT-en9 / MK-7902-001) - China Extension Study

NCT04865289 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

130

Enrollment

INDUSTRY

Sponsor class

Conditions

Endometrial Neoplasms

Interventions

DRUG: Lenvatinib
BIOLOGICAL: Pembrolizumab
DRUG: Paclitaxel
DRUG: Carboplatin

Sponsor

Merck Sharp & Dohme LLC

Collaborators

[object Object]